Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-79
Millions of yen (year-on-year change in operating expenses)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsInterim period of the fiscal year ending December 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit¥-392 million
Ordinary income¥-392 million
Net income¥-393 million
Selling, general and administrative expenses¥152 million
Full-year earnings forecast
Operating Expenses
900～1,300
Research and development costs
600～900
Other selling, general and administrative expenses
300～400
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Operating Expenses¥-79 million
- Research and development costs¥-58 million
- Other selling, general and administrative expenses¥-20 million
- Non-Operating Expenses¥-12 million
- Extraordinary losses¥-1 million
New initiatives
- Start of joint research with Kyushu University on a drug for the prevention and treatment of acute kidney injury
- Preparations to start the Phase 2a clinical trial of TMS-008
Key KPIsA metric the company considers important as a management benchmark.
- Planned number of participants to be enrolled in the ORION trial740 People
- Planned number of countries in which the ORION trial will be conducted20 Countries
- Planned number of sites at which the ORION trial will be conducted150 Facility
- Number of countries in which the ORION trial has been conducted, based on publicly disclosed results17 Countries
- Number of sites at which the ORION trial has been conducted, based on publicly disclosed results76 Facility
Number of employees
Number of Employees18 People
Record dateAs of the end of December 2025
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Interim period of the fiscal year ending December 2026 |
| Operating profit | ¥-392 million |
| Ordinary income | ¥-392 million |
| Net income | ¥-393 million |
| Selling, general and administrative expenses | ¥152 million |
| Full-year earnings forecast | Operating Expenses 900～1,300 / Research and development costs 600～900 / Other selling, general and administrative expenses 300～400 |
| Breakdown of Factors Affecting the Change | Factors Operating Expenses / Amount ¥-79 million, Factors Research and development costs / Amount ¥-58 million, Factors Other selling, general and administrative expenses / Amount ¥-20 million, Factors Non-Operating Expenses / Amount ¥-12 million, Factors Extraordinary losses / Amount ¥-1 million |
| Key KPIs | Indicator name Planned number of participants to be enrolled in the ORION trial / Value 740 People / Year on year against the same period last year Not disclosed, Indicator name Planned number of countries in which the ORION trial will be conducted / Value 20 Countries / Year on year against the same period last year Not disclosed, Indicator name Planned number of sites at which the ORION trial will be conducted / Value 150 Facility / Year on year against the same period last year Not disclosed, Indicator name Number of countries in which the ORION trial has been conducted, based on publicly disclosed results / Value 17 Countries / Year on year against the same period last year Not disclosed, Indicator name Number of sites at which the ORION trial has been conducted, based on publicly disclosed results / Value 76 Facility / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 18 People / Record date As of the end of December 2025 / Changes during the period and hiring plan Not disclosed |
| New initiatives | Start of joint research with Kyushu University on a drug for the prevention and treatment of acute kidney injury, Preparations to start the Phase 2a clinical trial of TMS-008 |
Items this document does not state (20)
Net SalesGross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although costs for the Phase 1 trial of TMS-008 were recorded in the interim period of the previous year, no significant costs were recorded in the current interim period, resulting in a ¥79 million decrease in operating expenses. In the second half, development costs for each pipeline, including TMS-007 (JX10) and TMS-008, as well as exploratory costs to expand the pipeline, are expected to increase.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.